84 related articles for article (PubMed ID: 38706610)
1. Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.
Hagerty BL; Pegna GJ; Xu J; Tai CH; Alewine C
Biomolecules; 2020 Jun; 10(7):. PubMed ID: 32605175
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers.
Skorupan N; Peer CJ; Zhang X; Choo-Wosoba H; Ahmad MI; Lee MJ; Rastogi S; Sato N; Yu Y; Pegna GJ; Steinberg SM; Kalsi SS; Cao L; Figg WD; Trepel JB; Pastan I; FitzGerald D; Alewine C
Front Oncol; 2024; 14():1386190. PubMed ID: 38706610
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Hassan R; Alewine C; Mian I; Spreafico A; Siu LL; Gomez-Roca C; Delord JP; Italiano A; Lassen U; Soria JC; Bahleda R; Thomas A; Steinberg SM; Peer CJ; Figg WD; Niederfellner G; Méresse Naegelen V; Pastan I
Cancer; 2020 Nov; 126(22):4936-4947. PubMed ID: 32870522
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma.
Alewine C; Ahmad M; Peer CJ; Hu ZI; Lee MJ; Yuno A; Kindrick JD; Thomas A; Steinberg SM; Trepel JB; Figg WD; Hassan R; Pastan I
Clin Cancer Res; 2020 Feb; 26(4):828-836. PubMed ID: 31792036
[TBL] [Abstract][Full Text] [Related]
5. Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin.
King EM; Mazor R; Çuburu N; Pastan I
J Immunol; 2018 Mar; 200(6):2038-2045. PubMed ID: 29431691
[TBL] [Abstract][Full Text] [Related]
6. Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1.
Mazor R; King E; Pastan I
Cell Immunol; 2018 Dec; 334():38-41. PubMed ID: 30213644
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic developments in pancreatic cancer.
Hu ZI; O'Reilly EM
Nat Rev Gastroenterol Hepatol; 2024 Jan; 21(1):7-24. PubMed ID: 37798442
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing antidrug antibody to emicizumab in patients with severe hemophilia A: Case report of a first noninhibitor patient and review of the literature.
Kizilocak H; Guerrera MF; Young G
Res Pract Thromb Haemost; 2023 Aug; 7(6):102194. PubMed ID: 37732158
[TBL] [Abstract][Full Text] [Related]
9. Sotorasib in
Strickler JH; Satake H; George TJ; Yaeger R; Hollebecque A; Garrido-Laguna I; Schuler M; Burns TF; Coveler AL; Falchook GS; Vincent M; Sunakawa Y; Dahan L; Bajor D; Rha SY; Lemech C; Juric D; Rehn M; Ngarmchamnanrith G; Jafarinasabian P; Tran Q; Hong DS
N Engl J Med; 2023 Jan; 388(1):33-43. PubMed ID: 36546651
[TBL] [Abstract][Full Text] [Related]
10. Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures.
Liu W; Tai CH; Liu X; Pastan I
Proc Natl Acad Sci U S A; 2022 Nov; 119(48):e2214928119. PubMed ID: 36409889
[TBL] [Abstract][Full Text] [Related]
11. Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxel.
Pegna GJ; Lee MJ; Peer CJ; Ahmad MI; Venzon DJ; Yu Y; Yuno A; Steinberg SM; Cao L; Figg WD; Donahue RN; Hassan R; Pastan I; Trepel JB; Alewine C
Cancer Med; 2023 Feb; 12(4):4236-4249. PubMed ID: 36208017
[TBL] [Abstract][Full Text] [Related]
12. Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline
Yu S; Agarwal P; Mamtani R; Symecko H; Spielman K; O'Hara M; O'Dwyer PJ; Schneider C; Teitelbaum U; Nathanson KL; Domchek SM; Reiss KA
JCO Precis Oncol; 2019 Dec; 3():1-11. PubMed ID: 35100679
[TBL] [Abstract][Full Text] [Related]
13. Cancer statistics, 2022.
Siegel RL; Miller KD; Fuchs HE; Jemal A
CA Cancer J Clin; 2022 Jan; 72(1):7-33. PubMed ID: 35020204
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]